MX2016010078A - Derivado de azaindol. - Google Patents
Derivado de azaindol.Info
- Publication number
- MX2016010078A MX2016010078A MX2016010078A MX2016010078A MX2016010078A MX 2016010078 A MX2016010078 A MX 2016010078A MX 2016010078 A MX2016010078 A MX 2016010078A MX 2016010078 A MX2016010078 A MX 2016010078A MX 2016010078 A MX2016010078 A MX 2016010078A
- Authority
- MX
- Mexico
- Prior art keywords
- jak3
- azaindole derivative
- salt
- inhibiting effect
- present
- Prior art date
Links
- 125000005334 azaindolyl group Chemical class N1N=C(C2=CC=CC=C12)* 0.000 title abstract 3
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 abstract 3
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
El propósito de la presente invención es proporcionar un compuesto novedoso que tiene un efecto selectivo inhibidor para JAK3 y que también tiene una excelente absorbancia oral; lo que es más, el propósito de la presente invención es proporcionar un agente farmacológico útil para, con base en un efecto inhibidor de JAK3, prevenir y/o tratar una enfermedad que involucra JAK3, en particular, artrítris reumatoide o esclerosis múltiple; se proporciona un derivado de azaindol que tiene un grupo cicloalquenilo, el cual es representado por la siguiente Fórmula (I), o una sal del mismo, y una composición farmacéutica que contiene al mismo: (ver Fórmula) en donde R1 a R4, m y n tienen el mismo significado que aquellos definidos en la descripción.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014019584 | 2014-02-04 | ||
| PCT/JP2015/053031 WO2015119126A1 (ja) | 2014-02-04 | 2015-02-04 | アザインドール誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016010078A true MX2016010078A (es) | 2016-10-07 |
| MX363295B MX363295B (es) | 2019-03-15 |
Family
ID=53777930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016010078A MX363295B (es) | 2014-02-04 | 2015-02-04 | Derivado de azaindol. |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9676773B2 (es) |
| EP (1) | EP3070086B1 (es) |
| JP (1) | JP5938533B2 (es) |
| KR (1) | KR101718299B1 (es) |
| CN (1) | CN105980383B (es) |
| AU (1) | AU2015215582B2 (es) |
| BR (1) | BR112016017981B1 (es) |
| CA (1) | CA2938186C (es) |
| DK (1) | DK3070086T3 (es) |
| ES (1) | ES2706306T3 (es) |
| HU (1) | HUE041934T2 (es) |
| MX (1) | MX363295B (es) |
| MY (1) | MY162435A (es) |
| PH (1) | PH12016501215B1 (es) |
| PL (1) | PL3070086T3 (es) |
| PT (1) | PT3070086T (es) |
| RU (1) | RU2649575C1 (es) |
| SG (1) | SG11201605072VA (es) |
| TR (1) | TR201820925T4 (es) |
| TW (1) | TWI652265B (es) |
| WO (1) | WO2015119126A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3330271T3 (pl) * | 2015-07-31 | 2022-12-19 | Taiho Pharmaceutical Co., Ltd. | Związek pirolo[2,3-d]pirymidyny lub jego sól |
| WO2018166855A1 (en) | 2017-03-16 | 2018-09-20 | Basf Se | Heterobicyclic substituted dihydroisoxazoles |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
| RU2006138621A (ru) | 2004-04-02 | 2008-05-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Азаиндолы, полезные в качестве ингибиторов rock и других протеинкиназ |
| US20060122213A1 (en) | 2004-06-30 | 2006-06-08 | Francoise Pierard | Azaindoles useful as inhibitors of protein kinases |
| CA2572058A1 (en) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| JP5122280B2 (ja) | 2004-06-30 | 2013-01-16 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼのインヒビターとして有用なアザインドール |
| US8921376B2 (en) | 2005-05-20 | 2014-12-30 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| EP1910358A2 (en) | 2005-07-14 | 2008-04-16 | Astellas Pharma Inc. | Heterocyclic janus kinase 3 inhibitors |
| KR100739632B1 (ko) * | 2005-12-21 | 2007-07-13 | 삼성전자주식회사 | 반도체 모듈 테스트 설비 |
| CN104650077A (zh) * | 2006-01-17 | 2015-05-27 | 沃泰克斯药物股份有限公司 | 适用作詹纳斯激酶抑制剂的吖吲哚类 |
| GB0702259D0 (en) * | 2007-02-06 | 2007-03-14 | Eisai London Res Lab Ltd | 7-azaindole derivatives |
| CN102372717B (zh) | 2010-08-20 | 2014-06-18 | 和记黄埔医药（上海）有限公司 | 吡咯并嘧啶类化合物及其用途 |
| WO2012158785A1 (en) * | 2011-05-17 | 2012-11-22 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| US8993756B2 (en) * | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
-
2015
- 2015-02-04 EP EP15746235.9A patent/EP3070086B1/en active Active
- 2015-02-04 MY MYPI2016702191A patent/MY162435A/en unknown
- 2015-02-04 RU RU2016135531A patent/RU2649575C1/ru active
- 2015-02-04 HU HUE15746235A patent/HUE041934T2/hu unknown
- 2015-02-04 CN CN201580007276.5A patent/CN105980383B/zh active Active
- 2015-02-04 DK DK15746235.9T patent/DK3070086T3/en active
- 2015-02-04 BR BR112016017981-1A patent/BR112016017981B1/pt active IP Right Grant
- 2015-02-04 CA CA2938186A patent/CA2938186C/en active Active
- 2015-02-04 WO PCT/JP2015/053031 patent/WO2015119126A1/ja not_active Ceased
- 2015-02-04 PT PT15746235T patent/PT3070086T/pt unknown
- 2015-02-04 JP JP2015560995A patent/JP5938533B2/ja active Active
- 2015-02-04 MX MX2016010078A patent/MX363295B/es unknown
- 2015-02-04 AU AU2015215582A patent/AU2015215582B2/en active Active
- 2015-02-04 TW TW104103792A patent/TWI652265B/zh active
- 2015-02-04 KR KR1020167020944A patent/KR101718299B1/ko active Active
- 2015-02-04 ES ES15746235T patent/ES2706306T3/es active Active
- 2015-02-04 PL PL15746235T patent/PL3070086T3/pl unknown
- 2015-02-04 TR TR2018/20925T patent/TR201820925T4/tr unknown
- 2015-02-04 US US15/112,070 patent/US9676773B2/en active Active
- 2015-02-04 SG SG11201605072VA patent/SG11201605072VA/en unknown
-
2016
- 2016-06-21 PH PH12016501215A patent/PH12016501215B1/en unknown
-
2017
- 2017-01-12 US US15/404,253 patent/US9782392B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
| WO2015101958A3 (en) | Inhibitors of glutaminase | |
| PH12016501977A1 (en) | 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES | |
| NZ729037A (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
| MX2017014035A (es) | Formas solidas novedosas. | |
| AU2018253590A1 (en) | Imidazopyridazine compounds | |
| MX2015010003A (es) | Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih). | |
| PH12016501988A1 (en) | Antibacterial compounds | |
| PH12018500378B1 (en) | Novel annelated phenoxyacetamides | |
| PH12018501709A1 (en) | Naphthridinedione derivatives | |
| PH12018500358A1 (en) | Compounds for use in an antibacterial applications | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| MX386902B (es) | Metodos para el tratamiento de trastornos cardiovasculares. | |
| MX2017007380A (es) | Compuestos organicos. | |
| PH12016501215A1 (en) | Azaindole derivative | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| PH12015502703A1 (en) | Pharmaceutical compositions | |
| WO2015181837A3 (en) | Novel compounds as anti-tubercular agents | |
| HK1228395A1 (en) | Antibacterial compounds |